FDA, Generics Industry Agree on Inspection Fees

According to reports in the New York Times and on FiercePharma, the FDA and the generic pharmaceutical industry has reach agreement on annual user fees of just under $300 million to cover inspections of foreign manufacturing plants every 2 years. It is being predicted that Congress will give its approval to this agreement.For more details see

• "Government, generic industry reach agreement on fees" by Liz Jones Hollis, published today on the FiercePharma web site.
• "Inspection deal aims to improve generic drugs" by Gardiner Harris in the New York Times from Saturday, August 13.